Iacta Alea Est: The Inexorable Advance of Tofacitinib in the Treatment of Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. A Case Report

Iacta Alea Est: The Inexorable Advance of Tofacitinib in the Treatment of Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. A Case Report

Rapidly progressive interstitial lung disease is typically associated with clinically amyopathic dermatomyositis and the anti-melanoma differentiation associated gene 5 antibody, a condition with high mortality and resistance to classic immunosuppression. Recent reports have described the efficacy o...

Full description

Bibliographic Details
Main Authors: Walter Conca, Ihab Weheba, Mohei-Eldin Abouzied, Abeer Abdelsayed, Yousif Aleyouni, Eid Al‐Mutairy, Nasir Bakshi, Mohammad Khalid
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Pharmacology
Subjects:
tofacitinib
dermatomyositis
anti Jo-1 antibody
rapidly progressive interstitial lung disease
ferritin
natural killer cell
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2020.585761/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2020.585761/full

Similar Items